Dyne Therapeutics (NASDAQ:DYN) Shares Gap Up to $25.46

Dyne Therapeutics, Inc. (NASDAQ:DYN) gapped up prior to trading on Tuesday . The stock had previously closed at $25.46, but opened at $26.44. Dyne Therapeutics shares last traded at $25.51, with a volume of 33,728 shares changing hands.

Wall Street Analysts Forecast Growth

Several analysts have recently issued reports on the stock. Raymond James increased their price target on shares of Dyne Therapeutics from $27.00 to $56.00 and gave the stock a “strong-buy” rating in a research report on Thursday, January 4th. Stifel Nicolaus increased their price target on shares of Dyne Therapeutics from $35.00 to $41.00 and gave the stock a “buy” rating in a research report on Wednesday, March 6th. Chardan Capital increased their price target on shares of Dyne Therapeutics from $20.00 to $31.00 and gave the stock a “buy” rating in a research report on Friday, March 8th. HC Wainwright reissued a “buy” rating and set a $36.00 price target on shares of Dyne Therapeutics in a research report on Wednesday, March 6th. Finally, Piper Sandler increased their price target on shares of Dyne Therapeutics from $27.00 to $29.00 and gave the stock an “overweight” rating in a research report on Wednesday, March 6th. One research analyst has rated the stock with a sell rating, seven have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $37.75.

Dyne Therapeutics Stock Performance

The stock has a market cap of $2.22 billion, a PE ratio of -6.46 and a beta of 0.95. The business has a 50-day moving average of $26.15 and a 200 day moving average of $18.06.

Dyne Therapeutics (NASDAQ:DYN) last posted its quarterly earnings results on Tuesday, March 5th. The company reported ($1.09) EPS for the quarter, missing the consensus estimate of ($0.92) by ($0.17). Equities analysts expect that Dyne Therapeutics, Inc. will post -3.25 EPS for the current fiscal year.

Insider Activity

In related news, SVP Richard William Scalzo sold 3,429 shares of the business’s stock in a transaction that occurred on Thursday, February 29th. The stock was sold at an average price of $27.50, for a total transaction of $94,297.50. Following the transaction, the senior vice president now directly owns 124,228 shares of the company’s stock, valued at approximately $3,416,270. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In related news, SVP Richard William Scalzo sold 3,429 shares of the business’s stock in a transaction that occurred on Thursday, February 29th. The stock was sold at an average price of $27.50, for a total transaction of $94,297.50. Following the transaction, the senior vice president now directly owns 124,228 shares of the company’s stock, valued at approximately $3,416,270. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Wildon Farwell sold 1,585 shares of the business’s stock in a transaction that occurred on Monday, March 11th. The stock was sold at an average price of $25.70, for a total value of $40,734.50. Following the transaction, the insider now directly owns 151,590 shares in the company, valued at $3,895,863. The disclosure for this sale can be found here. Insiders have sold 1,875,432 shares of company stock valued at $44,368,530 in the last three months. Corporate insiders own 20.77% of the company’s stock.

Hedge Funds Weigh In On Dyne Therapeutics

A number of institutional investors have recently made changes to their positions in the business. Fcpm Iii Services B.V. bought a new position in Dyne Therapeutics during the fourth quarter worth $81,543,000. Frazier Life Sciences Management L.P. bought a new position in Dyne Therapeutics during the fourth quarter worth $15,758,000. Commodore Capital LP bought a new position in Dyne Therapeutics during the fourth quarter worth $11,970,000. Vivo Capital LLC lifted its stake in Dyne Therapeutics by 58.0% during the first quarter. Vivo Capital LLC now owns 1,635,136 shares of the company’s stock worth $46,422,000 after purchasing an additional 600,000 shares during the last quarter. Finally, Braidwell LP lifted its stake in Dyne Therapeutics by 32.2% during the third quarter. Braidwell LP now owns 1,821,972 shares of the company’s stock worth $16,325,000 after purchasing an additional 444,100 shares during the last quarter. 96.68% of the stock is owned by institutional investors and hedge funds.

Dyne Therapeutics Company Profile

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.